Background/Objectives: Atorvastatin (ATR), an antihyperlipidemic drug with a potential antibacterial effect, was investigated in this study. Like other statins, ATR has been repurposed for several uses, ranging from anti-inflammatory to antimicrobial applications, and has demonstrated successful results. However, the efficacy of ATR is limited by its low solubility, indicating an opportunity for its encapsulation in a nanotechnology-based drug delivery system. Methods: Nanostructured lipid carrier (NLC) formulations were prepared using high-pressure homogenization and ultrasonication. The formulations were characterized, including their particle size, polydispersity index, zeta potential, encapsulation efficiency, and in vitro release. Antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli), and Staphylococcus aureus (S. aureus) was evaluated using the growth curve (bacterial growth over time) and well diffusion methods (zone of inhibition and minimum inhibitory concentration (MIC) determination). The crystal violet assay was employed to assess biofilm inhibition. Results: The NLC formulations were optimized, and the size and zeta potential of the blank nanoparticles were 130 ± 8.39 nm and −35 ± 0.5 mV, respectively. In comparison, the encapsulated NLCs had a size of 142 ± 52.20 nm and a zeta potential of −31 ± 1.41 mV. The average encapsulation efficiency was 94%, and 70% of the drug was released after 24 h. The ATR-loaded NLCs showed significantly enhanced antibacterial activity by reducing the minimum inhibitory concentration by 2.5-fold for E. coli, 1.8-fold for S. aureus, and 1.4-fold for MRSA, and promoting more effective bacterial growth inhibition. Notably, biofilm inhibition was significantly improved with ATR-NLCs, achieving 80% inhibition for S. aureus, 40% for E. coli, and 30% for MRSA, compared to free ATR (p < 0.001). These findings suggest that NLC encapsulation enhances ATR’s antimicrobial efficacy and biofilm suppression. Conclusions: This study identified NLCs as successful carriers of ATR, significantly enhancing its antibacterial efficacy and biofilm inhibition capabilities. This formulation, which shows antimicrobial potential against both Gram-positive and Gram-negative bacteria, should be further studied and developed against different resistant microbial strains.

This retrospective observational study aimed to assess category-specific side effect reporting trends for cosmetic products in the Saudi Arabian market. A total of 1714 reports were analyzed from the Saudi Food and Drug Authority’s (SFDA) Cosmovigilance Database over a four-year period (2020–2023). The analysis showed that 53.32% of reports were submitted by males consumer. Phone-based reporting was the most common method (51.16%), followed by submissions through the official vigilance system (45.80%). Reporting activity increased steadily over the years, reflecting enhanced consumer awareness and engagement. Skincare products were the most frequently implicated category, with sensitivity (12.00%) and redness (4.00%) being the top reported adverse effects. Violations were primarily associated with heavy metals and bacterial contamination. The study emphasizes the vital role of the SFDA’s cosmovigilance system in maintaining public health and supports continued efforts to promote safe cosmetic.

Invasive pulmonary aspergillosis (IPA) is a fatal fungal infection with a high mortality rate. Voriconazole (VCZ) is considered a first-line therapy for IPA and shows efficacy in patients for whom other antifungal treatments have been unsuccessful. The objective of this study was to develop a high-potency VCZ-loaded liposomal system in the form of a dry-powder inhaler (DPI) using the spray-drying technique to convert liposomes into a nanocomposite microparticle (NCMP) DPI, formulated using a thin-film hydration technique. The physicochemical properties, including size, morphology, entrapment efficiency, and loading efficiency, of the formulated liposomes were evaluated. The NCMPs were then examined to determine their drug content, production yield, and aerodynamic size. The L3NCMP was formulated using a 1:1 lipid/L-leucine ratio and was selected for in vitro studies of cell viability, antifungal activity, and stability. These formulated inhalable particles offer a promising approach to the effective management of IPA.

Background: Furosemide is a loop diuretic used extensively to treat adult and pediatric patients. In some hospitals, furosemide oral liquids are not available in stock, thus necessitating the extemporaneous preparation of the drug. This study evaluates the stability of on-the-spot formulations of furosemide oral suspensions from crushed tablets evaluated in various vehicles: Dextrose 50%, Dextrose 70%, Ora-Sweet, and Ora-Plus over 60 days. This examination was prompted by the frequent shortage of certain excipients in the hospital, leading to the need to switch to Dextrose 50% or Dextrose 70% when Ora-Sweet and Ora-Plus are out of stock. Methods: The extemporaneous furosemide oral suspensions were prepared following the same compounding method used in the pharmacy. The suspensions were maintained at 4 °C in the refrigerator and assessed immediately and later, on days 7, 14, 30, and 60. The assessed parameters included visual appearance, redispersion time, sedimentation volume, and pH levels for stability analysis. We also examined the drug content, dissolution of the suspension, and microbiological stability. Results: Initial examinations indicated that Dextrose 50% and Ora-Plus maintained pH levels and stable appearances, while significant changes, mainly in appearance and redispersion time, indicated the instability of Dextrose 70%. Ora-Sweet showed fluctuations but stabilized by day 30. Dissolution studies demonstrated that Ora-Plus had dissolution characteristics superior to the other formulations, while Dextrose 50% showed declining dissolution percentages over time. Overall, the Ora-Plus vehicle showed superior stability (60 days), followed by Ora-Sweet (30 days), while Dextrose 70% and Dextrose 50% showed shorter stability durations of 14 and 7 days, respectively. The microbiological test results showed no microbial growth. Conclusions: This study demonstrates that the vehicle used in extemporaneous furosemide suspensions critically affects their stability and performance. Ora-Plus emerged as the most suitable vehicle, maintaining physical, chemical, and microbiological stability over 60 days, with consistent pH, redispersion, and dissolution behavior. Ora-Sweet showed intermediate stability (30 days), while Dextrose 50% and 70% exhibited early instability—7 and 14 days, respectively—marked by sedimentation, poor redispersibility, and declining drug release. These findings underscore the importance of vehicle selection and regular stability monitoring in compounded formulations to ensure therapeutic reliability and patient safety.

Plazomicin (PLZ) is a novel aminoglycoside which has been recently approved by The US Food and Drug Administration for the treatment of complicated urinary tract infections including acute pyelonephritis, caused by certain Enterobacteriaceae, in adult patients with limited or no options for alternative treatment. This study focuses on the development of microwell-based photometric and fluorometric assays for the quantitative determination of PLZ in its bulk drug substance and commercial pharmaceutical formulations (Zemedri® injections). Both assays utilize the dual-function chromogenic and fluorogenic properties of the 4-fluoro-7-nitrobenzofurazan (NBD-F) probe. The reaction between PLZ and NBD-F, conducted in a borate buffer at pH 8, resulted in the formation of a colored and fluorescent reaction product. The product exhibited maximum light absorption at 473 nm and emitted fluorescence at 541 nm when excited at 473 nm. Factors influencing the reaction between PLZ and NBD-F were thoroughly investigated, and optimal conditions were determined. Under the optimized reaction conditions, calibration curves were generated to establish the relationship between absorbance and fluorescence intensities of the reaction product with the corresponding PLZ concentrations. The absorbance–concentration relation was linear in a PLZ concentration range of 20–800 μg mL⁻¹ with a limit of quantitation of 25 μg mL⁻¹, while the fluorescence–concentration relation was linear in the concentration range of 0.05–1.5 μg mL⁻¹ with a limit of quantitation of 0.08 μg mL⁻¹. Both assays underwent validation and were successfully applied to the quantitation of PLZ in its bulk drug substance and pharmaceutical formulations (injections) with satisfactory accuracy and precision. The eco-friendliness/greenness assessment of the assays demonstrated that both assays comply with the requirements of green analytical chemistry approaches. Furthermore, the proposed microwell assay plates allowed for the simultaneous handling of numerous samples with micro-volumes, enabling high-throughput analysis. In conclusion, this study represents the first evaluation of NBD-F as a dual-function probe for the microwell-based photometric and fluorometric determination of PLZ. The developed assays serve as valuable analytical tools for the quality control of PLZ's bulk drug substance and pharmaceutical formulations.

Background: Drug shortages represent a growing challenge to healthcare systems worldwide, affecting treatment continuity and patient outcomes. This study assessed the burden and perceived impact of drug shortages from both healthcare professionals’ and patients’ perspectives in a Saudi tertiary hospital. Methods: A cross-sectional survey was conducted in April 2025 at King Abdulaziz Medical City, Riyadh, Saudi Arabia. Convenience sampling was used to recruit healthcare professionals with at least two years of experience and adult outpatients. Structured questionnaires assessed shortage frequency, affected drug classes, perceived impacts, and management practices. The findings were descriptively analyzed and compared with the Saudi Food and Drug Authority (SFDA) national shortage data for the corresponding 12-month period. Results: A total of 230 healthcare professionals and 243 patients participated. Among healthcare professionals, 89.1% reported experiencing at least one drug shortage, with 38.3% encountering shortages more than ten times annually. Anti-infectives (36.5%) and analgesics (35.7%) were the most frequently reported classes. The most common response was prescribing alternative medications (77.4%), with 55.3% perceived as adequately effective and 30.8% as less effective. Delayed care was the most frequently reported consequence (44.0%). Among patients, 30.9% reported experiencing shortages, 46.7% reported some degree of health impact, and 28.1% incurred additional costs. Awareness and utilization of the SFDA reporting system were low in both groups. Comparison with SFDA data revealed discrepancies between hospital-reported and nationally reported shortages. Conclusions: Drug shortages were frequently reported and associated with perceived clinical and economic consequences. Gaps between hospital experiences and national reporting highlight limitations in current surveillance systems. Strengthening reporting mechanisms, communication, and supply chain coordination may improve the management of drug shortages.